Before deciding the "societal value" of the new medicine, its performance in clinical trials, possible side effects, and accessibility must be closely examined.
Lecanemab is the first drug proven to slow the progression of Alzheimer's. Its manufacturer Eisai calculated its societal value to determine a suitable price.
The research team is now taking the steps necessary for making the promising drug available on the commercial market at the earliest date possible.
There is a movement in Japan and the United States to connect supercomputers to study the novel coronavirus, which is raging through the world....
PARIS — Former French president Jacques Chirac died on September 26 at the age of 86, his family announced on the same day. The cause of...
